BVX20 is a human monoclonal antibody that binds to CD20. It can eliminate B cells by engaging the immune system. BVX20 is applicable in the study of relapsed or chemotherapy-resistant follicular B-cell non-Hodgkin lymphoma (NHL), as well as CD20-positive diffuse large B-cell non-Hodgkin lymphoma (NHL).
Target:
Immunology/Inflammation related
* VAT and and shipping costs not included. Errors and price changes excepted
